Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | PLG | P00747 | 1/20 | 0.75 |
| ▸ | PLAT | P00750 | 1/20 | 0.75 |
| ▸ | GABRR1 | P24046 | 5/20 | 0.46 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 2/20 | 0.44 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1965494 | 1.00 | LMNA (0.75) | LMNAPLGPLATGABRR1GABRR2 | |
| SCHEMBL29954120 | 1.00 | LMNA (0.75) | LMNAPLGPLATGABRR1GABRR2 | |
| SCHEMBL28816390 | 1.00 | LMNA (0.75) | LMNAPLGPLATGABRR1GABRR2 | |
| SCHEMBL5722332 | 1.00 | LMNA (0.75) | LMNAPLGPLATGABRR1GABRR2 | |
| SCHEMBL5503267 | 0.87 | LMNA (0.57) | LMNAPLGPLATGABRR1GABRR2 | |
| SCHEMBL9294167 | 0.87 | LMNA (0.57) | LMNAPLGPLATGABRR1GABRR2 | |
| SCHEMBL9504278 | 0.87 | LMNA (0.57) | LMNAPLGPLATGABRR1GABRR2 | |
| SCHEMBL30484839 | 0.87 | LMNA (0.57) | LMNAPLGPLATGABRR1GABRR2 | |
| SCHEMBL5503262 | 0.87 | LMNA (0.57) | LMNAPLGPLATGABRR1GABRR2 | |
| SCHEMBL9504271 | 0.87 | LMNA (0.57) | LMNAPLGPLATGABRR1GABRR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2023-03-16 | — | — | US | disclosed |
| EP-3950692-A1 | NOVEL TRICYCLIC COMPOUNDS | AbbVie Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3950692-A1 | NOVEL TRICYCLIC COMPOUNDS | AbbVie Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-109053742-B | Novel tricyclic compounds | ABBVIE 公司 | 2021-06-15 | — | — | CN | disclosed |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2021-03-04 | — | — | US | disclosed |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2021-03-04 | — | — | US | disclosed |
| US-RE47221-E1 | Tricyclic compounds | ABBVIE INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-RE47221-E1 | Tricyclic compounds | ABBVIE INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180291029-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2018-10-11 | — | — | US | disclosed |
| EP-3266786-A1 | NOVEL TRICYCLIC COMPOUNDS | AbbVie Inc. (US) | 2018-01-10 | — | — | EP | disclosed |
| US-8426411-B2 | Tricyclic compounds | ABBOTT LABORATORIES (US) | 2013-04-23 | — | — | US | disclosed |
| US-20110311474-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110311474-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110311474-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2011068881-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20090312338-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312338-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2009152133-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2009-12-17 | — | — | WO | disclosed |
| EP-0933993-B1 | SUBSTITUTED CYCLOPENTANE COMPOUNDS USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARM INC (US) | 2006-04-05 | — | — | EP | disclosed |
| US-6410594-B1 | VIRICIDES | BIOCRYST PHARMACEUTICALS, INC. | 2002-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180291029-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | LMNA 1836/4885PLG 3329/4885PLAT 3254/4885 |
| US-20090312338-A1 | Novel Tricyclic Compounds | CYP11B2, CYP11B1, ABCB1 | LMNA 1836/4885PLG 3329/4885PLAT 3254/4885 |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | LMNA 2521/4885PLG 3540/4885PLAT 3440/4885 |
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | LMNA 1836/4885PLG 3329/4885PLAT 3254/4885 |
| US-20110311474-A1 | Novel Tricyclic Compounds | CYP11B2, CYP11B1, ABCB1 | LMNA 2521/4885PLG 3540/4885PLAT 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.